drugset / Trial / NCT05175274

Colchicine Use for Primary Prevention of Coronary Artery Disease

NCT05175274

Phase 3 Not yet recruiting 6792 enrolled Qingdao Central Hospital Qingdao Municipal Hospital · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

Colchicine has been widely used as an anti-gout medicine in the past decades. Some recent clinical trials have proved that low-dose colchicine can be used as a secondary prevention drug for coronary artery disease because of its anti-inflammatory mechanism. However, the effect on primary prevention has not been observed sufficiently. The objective of this study is to determine whether colchicine reduces the incidence of CAD in patients and its safety for long-term use.

Timeline

Start
2022-12-06
Primary completion
2027-03-01
Completion
2028-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 0.5 mg